159 related articles for article (PubMed ID: 28205224)
1. MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Sheng Y; Ng CP; Lourie R; Shah ET; He Y; Wong KY; Seim I; Oancea I; Morais C; Jeffery PL; Hooper J; Gobe GC; McGuckin MA
Int J Cancer; 2017 May; 140(10):2351-2363. PubMed ID: 28205224
[TBL] [Abstract][Full Text] [Related]
2. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Liu L; Xiong Y; Xi W; Wang J; Qu Y; Lin Z; Chen X; Yao J; Xu J; Guo J
Oncotarget; 2017 Feb; 8(9):14995-15003. PubMed ID: 28122358
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T;
Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
6. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
7. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
[TBL] [Abstract][Full Text] [Related]
8. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
9. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
11. CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Chen X; Liu L; Wang J; Lin Z; Xiong Y; Qu Y; Wang Z; Yang Y; Guo J; Xu J
Urol Oncol; 2018 May; 36(5):242.e15-242.e21. PubMed ID: 29370961
[TBL] [Abstract][Full Text] [Related]
12. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Boers-Sonderen MJ; Desar IM; Fütterer JJ; Mulder SF; De Geus-Oei LF; Mulders PF; Van Der Graaf WT; Oyen WJ; Van Herpen CM
Anticancer Res; 2015 Oct; 35(10):5601-6. PubMed ID: 26408732
[TBL] [Abstract][Full Text] [Related]
13. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
[TBL] [Abstract][Full Text] [Related]
14. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma.
Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J
Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069
[TBL] [Abstract][Full Text] [Related]
15. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-Sunitinib Sequence: The Jury Is Out.
Albiges L; Escudier B
Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
[No Abstract] [Full Text] [Related]
17. Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Niinivirta M; Enblad G; Edqvist PH; Pontén F; Dragomir A; Ullenhag GJ
J Cancer Res Clin Oncol; 2017 Jun; 143(6):961-970. PubMed ID: 28260162
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
[TBL] [Abstract][Full Text] [Related]
20. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Buti S; Puligandla M; Bersanelli M; DiPaola RS; Manola J; Taguchi S; Haas NB
Ann Oncol; 2017 Nov; 28(11):2747-2753. PubMed ID: 28945839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]